Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 5Solid Tumors 4Primary Myelofibrosis 4Leukemia, Myeloid, Acute 4Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Solid Tumor 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoid Malignancy 1Leukemia, Myelomonocytic, Chronic 1Leukemia, B-Cell 1Leukemia 1Hepatitis C 1Hepatitis B 1Hematologic Neoplasms 1Fibrosis 1Carcinoma, Hepatocellular 1Advanced Lung Non-Squamous Non-Small Cell Carcinoma 1

Interventions

pembrolizumab 10Docetaxel 8senaparib 7Injections 7Capecitabine 7Paclitaxel 6Cisplatin 6Irinotecan 5Fluorouracil 5Leucovorin 4Cyclophosphamide 4Bevacizumab 4tislelizumab 3pertuzumab 3fludarabine 3atezolizumab 3Rifampin 3Oxaliplatin 3Itraconazole 3Gemcitabine 3ontuxizumab 2navoximod 2fluzoparib 2durvalumab 2Trastuzumab 2Nivolumab 2Midazolam 2Hydroxychloroquine 2Carboplatin 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumor × navitoclax × Clear all
NCT00888108 2012-05-22

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

Abbott

Phase 1 Completed
41 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡